Andrew J. Muir, MD, MHS Chief, Division of Gastroenterology Duke University School of Medicine Durham, North Carolina Treatment of Hepatitis C in Patients.

Slides:



Advertisements
Similar presentations
Slide 1 of 8 From DL Wyles, MD, at Atlanta, GA: April 10, 2013, IAS-USA. IAS–USA David L. Wyles, MD Associate Professor of Medicine University of California.
Advertisements

Interferon-free 3 DAA Plus Ribavirin Regimen in HCV Genotype 1-Infected Patients on Methadone or Buprenorphine 20 th International AIDS Conference Melbourne,
Hepatitis web study Hepatitis web study Hepatitis web study Hepatitis web study Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir +/- RBV in GT1b PEARL-II.
Hepatitis web study Hepatitis web study Hepatitis web study Hepatitis web study Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir + RBV in Liver Transplant.
Hepatitis web study Hepatitis web study Hepatitis web study Hepatitis web study Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir + RBV in GT1 SAPPHIRE-II.
Hepatitis web study Hepatitis web study Simeprevir + Sofosbuvir +/- Ribavirin in Genotype 1 COSMOS Trial Phase 2a, Treatment Naïve and Treatment Experienced.
Hepatitis web study Hepatitis web study Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I Phase 2b Treatment Naïve and Treatment Experienced.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in Treatment-Experienced GT1 with Cirrhosis SIRIUS Phase 2 Treatment Experienced Bourliere.
Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV Recurrence Following Liver Transplantation Phase 2 Charlton M, et al. Gastroenterology.
Hepatitis web study Hepatitis web study 3D + RBV in Liver Transplant Recipients with Recurrent HCV GT1 CORAL-I Phase 2 Treatment Naïve and Treatment Experienced.
Hepatitis web study Hepatitis web study 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) +/- RBV in GT1b PEARL-II Phase 3 Treatment Experienced Andreone.
Hepatitis web study Hepatitis web study 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in GT1 SAPPHIRE-II Phase 3 Treatment Experienced Zeuzem.
Kwo PY. NEJM 2014;371: CORAL-I  Design OBV/PTV/r + DSV + RBV Open label Phase II years Chronic HCV infection, genotype 1 Liver transplantation.
ALLY-1  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml) in genotype 1 DCV 60 mg qd + SOF 400 mg qd + RBV DCV 60 mg qd + SOF 400 mg qd + RBV Not randomised.
OBV/PTV/r + DSV + RBV Placebo Randomisation** 3 : 1 Double blind years Chronic HCV genotype 1 HCV RNA ≥ 10,000 IU/ml Failure to pre-treatment with.
OBV/PTV/r + DSV + RBV OBV/PTV/r + DSV Randomisation* 1 : 1 Open label years Chronic HCV infection Genotype 1b Prior failure to PEG-IFN + RBV HCV.
No prior therapy with PI
OBV/PTV/r Open label years Chronic HCV infection Genotype 1b Treatment-naïve or failure to PEG-IFN + RBV HCV RNA > 10,000 IU/ml Without or with cirrhosis*
COSMOS SOF + SMV + RBV SOF + SMV Randomisation 2 : 1 : 2 : 1* Open-label * Randomisation was stratified on genotype (1a or 1b) in both cohorts, IL28B in.
Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir in Genotype 3 ALLY-3 Study Phase 3 Treatment-Naïve and Treatment-Experienced Nelson DR,
SMV SOF 400 Open-label OPTIMIST-2 Study: SMV + SOF for genotype 1 and cirrhosis W12  Objective –Superiority of SVR 12 (HCV RNA historical control.
OBV/PTV/r + DSV + RBV OBV/PTV/r + DSV + placebo Randomisation* Partial blind years Chronic HCV infection Genotype 1 Treatment-naïve HCV RNA > 10,000.
SIRIUS Placebo LDV/SOF + placebo Randomisation* 1 : 1 Double-blind SIRIUS Study: LDV/SOF ± RBV for genotype 1 and cirrhosis with non response to prior.
ARV-trial.com C-SWIFT Study: grazoprevir/elbasvir + SOF in genotypes 1 or 3, with or without cirrhosis Randomisation 1 : 1 Open-label Design W4 W6 W8.
ION-1  Design LDV/SOF LDV/SOF + RBV Randomisation* 1 : 1 : 1 : 1 Open-label ION-1 Study: LDV/SOF + RBV for genotype 1 W24W12 ≥ 18 years Chronic HCV infection.
 Treatment regimens –Co-formulated ombitasvir (OBV)/paritaprevir (PTV)/rironavir (r) : 25/150/100 mg QD = 2 tablets –Dasabuvir (DSV) : 250 mg bid  Objective.
SOLAR-2 LDV/SOF + RBV Randomisation of the 7 groups 1 : 1 Open-label SOLAR-2 Study: LDV/SOF + RBV in decompensated and post-liver transplant with genotype.
SOLAR-1 LDV/SOF + RBV Randomisation* of the 7 groups 1 : 1 Open-label SOLAR-1 Study: LDV/SOF + RBV in advanced liver disease  Design W12W24 ≥ 18 years.
 Treatment regimens –Co-formulated ombitasvir (OBV)/paritaprevir (PTV)/rironavir (r) : 25/150/100 mg QD = 2 tablets –Dasabuvir (DSV) : 250 mg BID –RBV.
> 18 years Chronic HCV infection Genotype 1 Failure (relapse) to 4, 6 or 8 weeks of GZR/EBR + SOF in C-SWIFT Part A Compensated cirrhosis assessed by liver.
SOF/VEL 400/100 mg qd N = 500 N = 100 W12 Placebo > 18 years Chronic HCV infection Genotype 1, 2, 4, 5 or 6 Naïve or pre-treatment with IFN-based regimen.
OBV/PTV/r + DSV Open label Chronic HCV infection Genotype 1 Treatment-naïve HCV RNA > 1,000 IU/ml Chronic kidney disease with eGFR < 30 ml/min/1.73m 2.
 Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI, next observation carried backward DCV + SOF + RBV Randomised* 1:1 Open-label ALLY-3+ study: DCV.
SAPPHIRE-I Feld JJ. NEJM 2014;370: SAPPHIRE-I Study: ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin for genotype 1  Treatment regimens.
Treatment of Chronic HCV Genotype 3
Dore G. J Hepatol 2016; 64:19-28 MALACHITE TVR + PEG-IFN + RBV Randomisation Open-label years HCV genotype 1 HCV RNA > 10,000 IU/ml Naïve (MALACHITE-I)
Poordad F. NEJM 2014;368: D Phase IIa  Design  Treatment regimens – Paritaprevir/rironavir (PTV/r) : PTV 250 or 150 mg qd/ritonavir 100 mg qd (2.
Hepatitis web study Hepatitis web study Elbasvir-Grazoprevir in Treatment-Naïve HCV Genotype 1, 4 or 6 C-EDGE Treatment Naïve (TN) Phase 3 Treatment Naïve.
 Objective –SVR 12 (HCV RNA < 25 IU/ml), by ITT OBV/PTV/r + SOF + RBV OBV/PTV/r + SOF Not randomised Open-label QUARTZ-II Study: OBV/PTV/r + SOF for HCV.
No cirrhosis or compensated cirrhosis * No HBV or HIV coinfection
Design Randomisation* 1 : 1 Open-label W8 W12
ARV-trial.com RUBY-II Study: ombitasvir/paritaprevir/ritonavir + dasabuvir for HCV genotype 1a or 4 with severe renal impairment Design Open label W12.
Glecaprevir-Pibrentasvir in GT 1-6 with Renal Disease EXPEDITION-4
Sofosbuvir-Velpatasvir-Voxilaprevir in DAA-Naïve GT 1-6 POLARIS-2
Sofosbuvir-Velpatasvir-Voxilaprevir in GT 3 and Cirrhosis POLARIS-3
Design Single arm Open label W12 ≥ 18 years, HCV genotype 1 to 6
No HBV or HIV co-infection
Phase 3 Treatment-Naïve and Treatment-Experienced
Daclatasvir + Sofosbuvir in Genotype 3 ALLY-3 Study
Design No randomisation Open-label W12 W years HCV genotype 1
Phase 3 Treatment-Naïve and Treatment-Experienced
> 18 years Chronic HCV infection Compensated cirrhosis **
ARV-trial.com C-CREST study, Part B: uprifosbuvir (MK-3682)/GZR/ruzasvir (MK-8408) fixed-dose combination + RBV for genotypes 1, 2 and 3 - Phase II Randomisation.
Phase 3 Treatment-Naïve and Treatment-Experienced
Retreatment study: SOF/VEL + RBV in prior NS5A failure - Phase II
No cirrhosis or compensated cirrhosis** No HBV or HIV co-infection
Phase 3 Treatment-Naïve and Treatment-Experienced
ARV-trial.com RUBY-I Study, cohort 2: ombitasvir/paritaprevir/ritonavir + dasabuvir + RBV for HCV genotype 1 with renal impairment Design Open label W12.
LEAGUE-1 study: daclatasvir + SMV + RBV for genotype 1
No HBV or HIV co-infection
Phase 3 Treatment Naïve HIV Coinfection
Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I
Design W12 Randomisation * Open-label
ARV-trial.com IMPACT Study: SMV + DCV + SOF in HCV genotype 1 with decompensated liver disease Design Open label ≥ 18 years Chronic HCV infection Genotype.
GS-US Study: SOF/VEL + GS-9857 in genotype 1 - Phase II
Phase 3 Treatment-Naïve and Treatment-Experienced
Phase 2b Treatment Naïve and Treatment Experienced
LDV/SOF ± RBV in genotype 3 or 6 – Phase 2
ARV-trial.com C-CREST study, Part B: uprifosbuvir (MK-3682)/GZR/ruzasvir (MK-8408) fixed-dose combination + RBV for genotypes 1, 2 and 3 - Phase II Randomisation.
Phase 3 Treatment-Naïve and Treatment-Experienced
Presentation transcript:

Andrew J. Muir, MD, MHS Chief, Division of Gastroenterology Duke University School of Medicine Durham, North Carolina Treatment of Hepatitis C in Patients With Cirrhosis Recorded on 10/24/14

Slide 2 of 33 Disclosure Dr Muir has received grants and research support from AbbVie, Achillion Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Roche, and Vertex Pharmaceuticals, Inc. He has served as a consultant to AbbVie, Achillion Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Salix Pharmaceuticals, and Vertex Pharmaceuticals, Inc. (Updated 9/3/14)

Slide 3 of 33 Outline Definitions and diagnostic approach Treatment – Candidacy – Efficacy – Adverse events Decompensated cirrhosis

Slide 4 of 33 Case 54-year-old man presents with new diagnosis – History: no ascites, encephalopathy, GI bleeding – Examination: mentally clear, no ascites or edema – Laboratory data:  AST 60 U/L, ALT 75 U/L, t bili 1.2 mg/dL  Albumin 3.9 gm/dL, creatinine 1.0 mg/dL  Platelet 110 x 10 9 /L  PT-INR 1.1  HCV RNA 1,100,000 IU/mL  Genotype 1a Clinical questions – Does the patient need treatment? – What is the stage of liver disease?

Definitions and Diagnostic Approach

Slide 6 of 33 DiBisceglie A. Hepatology 2000 Cirrhosis 20 % Faster progression with older age at infection alcohol HIV infection post-transplant Acute HCV Chronic HCV % years HCV natural history

Slide 7 of 33 Liver fibrosis staging F1: portal fibrosis F2: portal fibrosis with few septa F3: septal fibrosis (bridging) F4: cirrhosis Bedossa P. Hepatology 1996

Slide 8 of 33 Gold standard Invasive  Morbidity (3/1,000)  Mortality (1/10,000) Observer variability Sampling error Costly Rockey DC. Hepatology 2009; Regev A. Am J Gastroenterol 2002 Liver biopsy

Slide 9 of 33 Alternatives to liver biopsy Alternative approaches – Serum markers  Standard laboratory tests: APRI, FIB-4  Commercial assays – Radiographic tests  Elastography Limitations – Ability to distinguish F1 versus F2, etc  Better to differentiate advanced versus early – Serologies impacted by inflammation – Indeterminate outcomes common Lin ZH. Hepatology 2011; Vallet-Pichard. Hepatology 2007; Myers RP. Dig Dis Sci 2003; Friedrich-Rust M. Gastroenterology 2006

Slide 10 of 33 Recommendations AASLD/IDSA/IAS–USA Guidance – An assessment of the degree of hepatic fibrosis, using noninvasive testing or liver biopsy, is recommended. Ongoing assessment of liver disease is recommended for persons in whom therapy is deferred.

Treatment

Slide 12 of 33 Who needs treatment? AASLD/IDSA/IAS–USA Guidance – Treatment is recommended for patients with chronic HCV infection. Treatment is assigned the highest priority for those patients with advanced fibrosis (Metavir F3), those with compensated cirrhosis (Metavir F4), liver transplant recipients, and patients with severe extrahepatic hepatitis C.

Slide 13 of 33 Genotype 2 AASLD/IDSA/IAS–USA Guidance – Sofosbuvir + ribavirin x 12 weeks Peginterferon-α, ribavirin + sofosbuvir Treatment naiveRecommended PEG/RBV nonrespondersRecommended*Alternative * Patients with cirrhosis may benefit by extension of treatment to 16 weeks.

Slide 14 of 33 Genotype 2 sofosbuvir + ribavirin SOF/RBV PEG/RBV SOF/RBV x 12 weeks SOF/RBV x 16 weeks FISSION (treatment naive) FUSION (treatment experienced) Lawitz E. NEJM 2013; Jacobson IM. NEJM 2013

Slide 15 of 33 Genotype 3 AASLD/IDSA/IAS–USA Guidance – Sofosbuvir + ribavirin x 24 weeks Peginterferon-α, ribavirin + sofosbuvir Treatment naiveRecommendedAlternative PEG/RBV nonrespondersRecommendedAlternative

Slide 16 of 33 Genotype 3 sofosbuvir + ribavirin SOF/RBV PEG/RBV SOF/RBV x 12 weeks SOF/RBV x 16 weeks / FISSION (treatment naive) FUSION (treatment experienced) Lawitz E. NEJM 2013; Jacobson IM. NEJM 2013

Slide 17 of 33 VALENCE study Amended to treat GT 3 for 24 weeks Treatment naive and experienced 12 and 24 weeks similar safety profile Zeuzem S. NEJM 2014 Genotype 3 sofosbuvir + ribavirin

Slide 18 of 33 Afdhal N. NEJM 2014; Poordad F. NEJM 2014; Sulkowski M. NEJM 2014 SVR rates > 90% in genotype 1 – Are outcomes lower in patients with cirrhosis? Sofosbuvir, ledipasvir +/- ribavirin Sofosbuvir, daclatasvir +/- ribavirin ABT450/ritonavir, ombitasvir, dasabuvir, ribavirin Simeprevir, sofosbuvir +/- ribavirin Genotype 1

Slide 19 of 33 Sofosbuvir phase 3 studies – Genotypes 1-3 – SOF/RBV and PEG/RBV/SOF Foster G. EASL 2014 FactorOdds ratioP-value Treatment experienced Male Weight > 75 kg IL28B non-CC3.4< Cirrhosis4.0< HCV RNA > 800,000 IU/mL4.7< Predictors of relapse

Slide 20 of 33 Sofosbuvir phase 3 studies – Genotypes 1-3 – SOF/RBV and PEG/RBV/SOF Foster G. EASL Predictors of SVR

Slide 21 of 33 Poordad F. NEJM 2014 Treatment in cirrhosis Population – 380 Child Pugh Class A cirrhosis (compensated) – Treatment naive and previously treated Interferon-free combination – Protease inhibitor ABT-450 with ritonavir (ABT-450/r) – NS5A inhibitor ombitasvir (ABT-267) – Nonnucleoside polymerase inhibitor dasabuvir (ABT-333) – Ribavirin Design – Phase 3, randomized, open label – Duration 12 versus 24 weeks

Slide 22 of 33 Poordad F. NEJM 2014 Treatment in cirrhosis

Slide 23 of 33 Poordad F. NEJM 2014 Treatment in cirrhosis

Slide 24 of 33 Poordad F. NEJM 2014 Variable12-week group (N = 208) 24-week group (N = 172) Any adverse event191 (91.8%)156 (90.7%) AE leading to discontinuation4 (1.9%)4 (2.3%) Serious adverse events13 (6.2%)8 (4.7%) Deaths1 (0.5%)0 Treatment in cirrhosis

Slide 25 of 33 Poordad F. NEJM 2014 Common adverse events12-week group (N = 208) 24-week group (N = 172) Fatigue68 (32.7%)80 (46.5%) Headache58 (27.9%)53 (30.8%) Nausea37 (17.8%)35 (20.3%) Pruritus38 (18.3%)33 (19.2%) Diarrhea30 (14.4%)29 (16.9%) Asthenia29 (13.9%)22 (12.8%) Rash23 (11.1%)25 (14.5%) Irritability15 (7.2%)21 (12.2%) Treatment in cirrhosis

Slide 26 of 33 Poordad F. NEJM 2014 Laboratory results12-week group (N = 208) 24-week group (N = 172) ALT, grade 3 or 46 (2.9%)0 AST, grade 3 or 41 (0.5%)0 Total bilirubin, grade 3 or 428 (13.5%)9 (5.2%) Anemia Hemoglobin < 10 gm/dL103 (49.5%)97 (56.4%) Hemoglobin 8-10 gm/dL12 (5.8%)18 (10.5%) Hemoglobin gm/dL2 (1.0%)1 (0.6%) Hemoglobin < 6.5 gm/dL1 (0.5%)0 Treatment in cirrhosis

Decompensated Cirrhosis

Slide 28 of 33 Decompensated cirrhosis With decompensated cirrhosis, how much better can the liver get? Will this be like HBV? Disclaimer for new agents Have they been studied in decompensated cirrhosis? Simeprevir – increased exposure with Child Pugh class B so use with caution

Slide 29 of 33 Decompensated cirrhosis Sofosbuvir + ribavirin, interim results Afdhal N. EASL Patients, N = 50 – HCV genotypes 1-4 – HVPG ≥ 6 mmHg – Child Pugh A 40%, B 60% Treatment – Arm 1: SOF/RBV x 48 weeks – Arm 2: Observation x 24 weeks then SOF/RBV x 48 weeks Discontinuations – Arm 1: 1 AE, 1 nonresponder, 1 withdrew – Arm 2: 2 disease progression, 1 withdrew, 1 LTFU

Slide 30 of 33 Afdhal N. EASL AscitesHepatic encephalopathy Week SOF/RBV N=25 Obs N=25 SOF/RBV N=25 Obs N=25 Baseline6952 Week Week Decompensated cirrhosis Sofosbuvir + ribavirin, interim results

Slide 31 of 33 Gane EJ. EASL Patients, N = 20 – Genotype 1 – Child Pugh class B – Ascites 4 (20%) – Encephalopathy 6 (30%) Duration: 12 weeks Decompensated cirrhosis Sofosbuvir + ledipasvir

Slide 32 of 33 Early positive signs More data needed in new regimens Long-term outcomes important Survival Complications of portal hypertension With decompensated cirrhosis, how much better can the liver get? Decompensated cirrhosis

Slide 33 of 33 Summary All patients with HCV need an assessment of fibrosis – Patients with advanced fibrosis or cirrhosis should be prioritized for treatment HCV treatment is safe and effective in patients with compensated cirrhosis – Sofosbuvir and ribavirin are effective for genotype 2/3 – Multiple interferon-free regimens have been developed for genotype 1 – Adverse events are generally mild with interferon-free regimens – Interferon-free regimens are well tolerated by patients with decompensated cirrhosis, and the long-term effectiveness is under investigation